Document details

Position statement on bioresorbable vascular scaffolds in Portugal

Author(s): Teles, R. cv logo 1 ; Pereira, H. cv logo 2 ; Cyrne-Carvalho, H. cv logo 3 ; Patrício, L. cv logo 4 ; Santos, R. cv logo 5 ; Baptista, J. cv logo 6 ; Pipa, J. cv logo 7 ; Farto-Abreu, P. cv logo 8 ; Faria, H. cv logo 9 ; Ramos, S. cv logo 10 ; Gama-Ribeiro, V. cv logo 11 ; Martins, D. cv logo 12 ; Almeida, M. cv logo 13

Date: 2013

Persistent ID: http://hdl.handle.net/10400.16/1721

Origin: Repositório Científico do Centro Hospitalar do Porto

Subject(s): Angioplastia coronária; Bioersorbable vascular scaffolds; Coronary angioplasty; Diabetes; Diabetic; Intervenção coronária percutânea; Percutaneous coronary intervention; Stent; Suportes vasculares restaurativos transitórios


Description
BACKGROUND: Bioresorbable vascular scaffolds (BVS) were recently approved for percutaneous coronary intervention in Europe. The aim of this position statement is to review the information and studies on available BVS, to stimulate discussion on their use and to propose guidelines for this treatment option in Portugal. METHODS AND RESULTS: A working group was set up to reach a consensus based on current evidence, discussion of clinical case models and individual experience. The evidence suggests that currently available BVS can produce physiological and clinical improvements in selected patients. There are encouraging data on their durability and long-term safety. Initial indications were grouped into three categories: (a) consensual and appropriate - young patients, diabetic patients, left anterior descending artery, long lesions, diffuse disease, and hybrid strategy; (b) less consensual but possible - small collateral branches, stabilized acute coronary syndromes; and (c) inappropriate - left main disease, tortuosity, severe calcification. CONCLUSION: BVS are a viable treatment option based on the encouraging evidence of their applicability and physiological and clinical results. They should be used in appropriate indications and will require technical adaptations. Outcome monitoring and evaluation is essential to avoid inappropriate use. It is recommended that medical societies produce clinical guidelines based on high-quality registries as soon as possible.
Document Type Article
Language English
delicious logo  facebook logo  linkedin logo  twitter logo 
degois logo
mendeley logo

Related documents



    Financiadores do RCAAP

Fundação para a Ciência e a Tecnologia Universidade do Minho   Governo Português Ministério da Educação e Ciência Programa Operacional da Sociedade do Conhecimento EU